Fertility benefits company Progyny (NASDAQ:PGNY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 16.5% year on year to $324 million. The company expects next quarter’s revenue to be around $317.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.7% above analysts’ consensus estimates.
Is now the time to buy PGNY? Find out in our full research report (it’s free).
Progyny (PGNY) Q1 CY2025 Highlights:
- Revenue: $324 million vs analyst estimates of $308.7 million (16.5% year-on-year growth, 5% beat)
- Adjusted EPS: $0.48 vs analyst estimates of $0.45 (7.7% beat)
- Adjusted EBITDA: $57.79 million vs analyst estimates of $54.71 million (17.8% margin, 5.6% beat)
- The company slightly lifted its revenue guidance for the full year to $1.21 billion at the midpoint from $1.2 billion
- Management raised its full-year Adjusted EPS guidance to $1.59 at the midpoint, a 1.3% increase
- EBITDA guidance for the full year is $196.5 million at the midpoint, in line with analyst expectations
- Operating Margin: 7.5%, in line with the same quarter last year
- Free Cash Flow Margin: 14.5%, up from 8.9% in the same quarter last year
- Sales Volumes rose 9.2% year on year (12.4% in the same quarter last year)
- Market Capitalization: $2 billion
StockStory’s Take
Progyny’s first quarter results reflected increased client adoption and higher member engagement, with management attributing revenue growth to a rise in covered lives and continued demand for its fertility and women’s health solutions. CEO Pete Anevski pointed to shifting demographic trends, such as later family planning among women, as key factors driving the need for Progyny’s services. He also noted, "Employers can proactively manage these risks through Progyny’s comprehensive solution," referencing the company’s role in addressing high-risk pregnancies and related costs for employers.
Looking ahead, management raised both revenue and adjusted earnings guidance for the year, citing a healthy sales pipeline and early positive feedback on new service modules. CFO Mark Livingston cautioned that future margins could moderate due to ongoing investments but expects full-year gross margin expansion versus last year. The company continues to monitor macroeconomic headwinds and client decision timelines, but Anevski said, "We entered this season feeling well positioned," emphasizing stable demand across diverse industries.
Key Insights from Management’s Remarks
Progyny’s management identified several factors shaping Q1 results and the outlook for the year, including shifts in member demographics, product portfolio expansion, and sales pipeline activity.
- Member Demographic Shifts: Management highlighted ongoing societal trends of women postponing childbirth into their 30s and 40s, which increases the prevalence of infertility and drives demand for fertility benefits.
- New Product Modules: Recent launches in maternity, postpartum, and menopause support are seeing strong market interest, especially the menopause product due to its broader addressable audience. Management expects these modules to deepen client relationships over time.
- Sales Pipeline Activity: The current pipeline is comparable in dollar value to last year, but average covered lives per opportunity are slightly lower, which management attributes to timing and macroeconomic factors. However, there is no apparent slowdown in employer decision-making or RFP activity.
- Client Retention and Upsell: Approximately 20–25% of existing clients typically expand their suite of services annually, with last year’s growth in upsells reaching 30%, boosted by new women’s health solutions.
- Transition of Large Client: Revenue this quarter included contributions from a large former client under a transition of care agreement, but even excluding this, core business growth remained robust. Management emphasized that member base expansion continues despite client churn.
Drivers of Future Performance
Management expects future performance to be shaped by a combination of sustained employer demand for women’s health benefits, ongoing portfolio investments, and macroeconomic conditions.
- Portfolio Investments Continue: Ongoing investments in platform and product capabilities, including integration of recent acquisitions, are expected to support long-term growth but may temper short-term profit margins.
- Stable Demand Environment: Management sees consistent demand from employers seeking to address shifting workforce demographics and retain talent, though some uncertainty remains due to broader economic factors.
- Sales and Upsell Strategy: The company’s focus on expanding relationships with existing clients through upsells and cross-selling of new modules is expected to contribute meaningfully to revenue growth in future periods.
Top Analyst Questions
- Anne Samuel (JPMorgan): Asked about muted seasonality in cycles per utilizer for Q2; management cited guidance caution due to uncertainty, not a change in underlying trends.
- Jailendra Singh (Truist Securities): Questioned potential delays in employer RFPs for 2026 launches; management said there was no slowdown in decision-making or sales cycles.
- Michael Cherny (Leerink Partners): Inquired about which new women’s health modules are seeing the most engagement; management pointed to higher initial uptake for the menopause product due to its broad applicability.
- David Michael (BTIG): Sought clarity on the impact of potential tariffs on specialty medications; management indicated minimal current impact and flexibility to mitigate any future cost increases.
- Sarah James (Cantor Fitzgerald): Asked for more detail on gross margin expansion and investment spending; management confirmed ongoing investments in platform and product capabilities totaling about $15 million for the year.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will monitor (1) the progress and adoption rates of Progyny’s new service modules, particularly in maternity and menopause support; (2) the pace and scale of new client acquisitions and upsell activity within the existing client base; and (3) the company’s ability to manage investments while maintaining or expanding margins. We will also watch for any macroeconomic shifts or regulatory changes that could influence employer benefit decisions.
Progyny currently trades at a forward P/E ratio of 14.2×. At this valuation, is it a buy or sell post earnings? See for yourself in our free research report.
Stocks That Trumped Tariffs in 2018
Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.